Herb-drug interaction studies of herbs used in treatment of cardiovascular disorders-A narrative review of preclinical and clinical studies
- PMID: 31908085
- DOI: 10.1002/ptr.6585
Herb-drug interaction studies of herbs used in treatment of cardiovascular disorders-A narrative review of preclinical and clinical studies
Abstract
About 70% of the world population is currently using medicinal herbs as complementary or alternative medicine, which is increasing at a tremendous pace in both developed and developing countries in the last two decades (World Health Organization Medicines Strategy 2002-2005). This increase in consumer demand of medicinal herbs continues despite the rarity of scientific data to establish their safety and efficacy profile. Its popularity is also attributed to several factors, including easy availability, cost effectiveness leading to better purchasing power and general perception that they are safe. Herbs are often administered concomitantly with therapeutic drugs for the treatment of major ailments, raising the potential for herb-drug interactions (HDIs). The major pathways postulated for HDIs involves the cytochrome P450 (CYP450)-mediated inhibition or induction and transport and efflux proteins. In our review, we highlight frequently used herbal medicines for the treatment of cardiovascular disorders (CVD), their established HDIs studied using in vitro tools and in vivo pharmacokinetic and pharmacodynamic assays and case reports. Herbs have been divided into different sections on the basis of availability of HDI data in relevance to cardiovascular drugs: herbs reported to interact with cardiac drugs, herbs yet to be reported for interaction with drugs of any class and herbs reported to interact with drugs of other therapeutic category but not with cardiac drugs. The amount of active phytoconstituents present in the selected herbs and their extent of bioavailability are also mentioned. This review can serve as a quick reference database for physicians and health care professionals involved in CVD treatment, aimed at maximizing clinical outcomes with reduction in adverse and toxic effects.
Keywords: CYP inhibition; cardiovascular diseases; cardiovascular drugs; cardiovascular herbs; herb-drug interaction; herbs.
© 2020 John Wiley & Sons, Ltd.
Similar articles
-
Interactions of herbs with cytochrome P450.Drug Metab Rev. 2003 Feb;35(1):35-98. doi: 10.1081/dmr-120018248. Drug Metab Rev. 2003. PMID: 12635815 Review.
-
Herb-drug interactions in diabetes mellitus: A review based on pre-clinical and clinical data.Phytother Res. 2021 Sep;35(9):4763-4781. doi: 10.1002/ptr.7108. Epub 2021 Apr 28. Phytother Res. 2021. PMID: 33908677 Review.
-
Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs?J Ethnopharmacol. 2016 Feb 17;179:253-64. doi: 10.1016/j.jep.2015.12.031. Epub 2015 Dec 23. J Ethnopharmacol. 2016. PMID: 26723469 Review.
-
Herb-drug interactions between Panax notoginseng or its biologically active compounds and therapeutic drugs: A comprehensive pharmacodynamic and pharmacokinetic review.J Ethnopharmacol. 2023 May 10;307:116156. doi: 10.1016/j.jep.2023.116156. Epub 2023 Feb 6. J Ethnopharmacol. 2023. PMID: 36754189 Review.
-
Herb-Drug Interactions in Neurological Disorders: A Critical Appraisal.Curr Drug Metab. 2018;19(5):443-453. doi: 10.2174/1389200218666171031123738. Curr Drug Metab. 2018. PMID: 29086684 Review.
Cited by
-
Metabolism-involved drug interactions with traditional Chinese medicines in cardiovascular diseases.J Food Drug Anal. 2022 Sep 15;30(3):331-356. doi: 10.38212/2224-6614.3421. J Food Drug Anal. 2022. PMID: 39666289 Free PMC article. Review.
-
The Use of Natural Products for Preventing Cognitive Decline/Providing Neuroprotection.Handb Exp Pharmacol. 2025;287:207-237. doi: 10.1007/164_2024_732. Handb Exp Pharmacol. 2025. PMID: 39333382 Review.
-
The pharmacokinetics effects of the MCAO model on senkyunolide I in pseudo germ-free rats after oral co-administration of Chuanxiong and warfarin.Front Pharmacol. 2025 Aug 1;16:1577757. doi: 10.3389/fphar.2025.1577757. eCollection 2025. Front Pharmacol. 2025. PMID: 40822474 Free PMC article.
-
Safety Aspects of Herb Interactions: Current Understanding and Future Prospects.Curr Drug Metab. 2024;25(1):28-53. doi: 10.2174/0113892002289753240305062601. Curr Drug Metab. 2024. PMID: 38482621 Review.
-
Quasi-Irreversible Inhibition of CYP2D6 by Berberine.Pharmaceutics. 2020 Sep 24;12(10):916. doi: 10.3390/pharmaceutics12100916. Pharmaceutics. 2020. PMID: 32987920 Free PMC article.
References
REFERENCES
-
- AARP and National Center for Complementary and Alternative Medicine. (2011). Complementary and alternative medicine: What people aged 50 and older discuss with their healthcare providers. Consumer Survery Report, (April), 1-14.
-
- Ahmmed, S. K. M., Mukherjee, P. K., Bahadur, S., Kar, A., Al-Dhabi, N. A., & Duraipandiyan, V. (2015). Inhibition potential of Moringa oleifera Lam on drug metabolizing enzymes. Indian Journal of Traditional Knowledge, 14(4), 614-619.
-
- Al-Ali, M., Wahbi, S., Twaij, H., & Al-Badr, A. (2003). Tribulus terrestris: Preliminary study of its diuretic and contractile effects and comparison with Zea mays. Journal of Ethnopharmacology, 85(2-3), 257-260.
-
- Amacher, D. E. (2010). The effects of cytochrome P450 induction by xenobiotics on endobiotic metabolism in pre-clinical safety studies. Toxicology Mechanisms and Methods, 20, 159-166.
-
- Andallu, B., & B. (2012). Hypoglycmic, diuretic and hypocholesterolemic effect of winter cherry (Withania somnifera, Dunal) root. Indian Journal of Experimental Biology, 3, 607-609.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources